PITTSBURGH — Mylan's sales ticked up slightly in second quarter 2013, compared with the same period last year, the company said.
The Pittsburgh-based generic drug maker reported sales of $1.7 billion, a 1% increase over second quarter 2012's $1.69 billion. For the six-month period that ended June 30, sales were $3.33 billion, a 2% increase over $3.27 billion during the same period last year.
Profits for the quarter were $177.7 million, compared with $138.6 million in second quarter 2012, while profits for the six months ended June 30 were $284.6 million, compared with $267.6 million during the same period last year.
"Our second-quarter results once again demonstrate the strength of our diverse global platform," Mylan CEO Heather Bresch said.